search

Active clinical trials for "Huntington Disease"

Results 51-60 of 236

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious,...

All Diagnosed Health ConditionsADD/ADHD59 more

We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.

Recruiting6 enrollment criteria

Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression

Huntington Disease

Intro Huntington's disease (HD) patients suffer from motor, cognitive and behavioral impairments, with heterogeneous phenotypes and variable time course. This leads to a high variance of HD markers, none of which is currently sensitive enough to 1) measure disease progression from small cohort data, 2) predict disease entry in carriers of the HD mutation (during the prodromal phase or in patients considered asymptomatic: pre-HD patients), and 3) measure a significant evolution of the state of pre-HD patients over a time window compatible with the realization of clinical trials (about 2/3 years). Moreover, the markers of HD do not allow a fine stratification of the patients. Hypothesis/Objective Our objectives are 1) to evaluate the sensitivity of new markers and assessment tools for symptomatic (HD) and presymptomatic (pre-HD) patients, 2) to define a model of disease progression, and 3) to establish an enrichment strategy to improve patient selection for future therapeutic trials. Method We will evaluate newly developed cognitive tests, multimodal imaging techniques, biological markers and use innovative statistical approaches. We will follow 60 patients with the mutation responsible for MH (40 presymptomatic pre-MH patients, 20 symptomatic MH patients) and 20 healthy volunteers (controls) over a 24-month period.

Not yet recruiting42 enrollment criteria

N- Homocysteinylated Huntingtin in Huntington's Disease

Huntington Disease

Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin) human control cell lines, unmutated Huntingtin

Not yet recruiting8 enrollment criteria

Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease...

Huntington's Disease

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease (HD).

Terminated31 enrollment criteria

Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease...

Huntington Disease

Phase A: Recruit 50 patients with HD, and their caregivers, to complete a neuropsychiatric and quality of life battery of scales at baseline. Have these 50 patients complete a formal psychiatric assessment with a psychiatrist within 2 weeks of this clinical battery, and the results of these 2 types of assessments will be compared to establish the level of agreement between clinical rating scales and formal psychiatric assessment. Phase B: Continue to follow Phase A cohort longitudinally and administer neuropsychiatric and quality of life battery at 6 months, 12 months, and 18 months form baseline. Recruit an additional 50 patients, administer the same neuropsychiatric and quality of life battery at baseline, implement medication and counseling intervention according to a standard of care protocol, and follow up with the same neuropsychiatric and quality of life battery at 6, 12, and 18 months.

Active15 enrollment criteria

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With...

Huntington Disease

WVE-HDSNP1-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120101 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism, rs362307 (SNP1). To participate in the study, patients must have completed the Phase 1b/2a clinical study WVE-HDSNP1-001.

Terminated6 enrollment criteria

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With...

Huntington Disease

WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism, rs362331 (SNP2). To participate in the study, patients must have completed the Phase 1b/2a clinical study WVE-HDSNP2-001.

Terminated4 enrollment criteria

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Huntington's Disease

PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).

Terminated11 enrollment criteria

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple...

Huntington Disease

To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.

Terminated27 enrollment criteria

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's...

Huntington's Disease

The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).

Terminated7 enrollment criteria
1...567...24

Need Help? Contact our team!


We'll reach out to this number within 24 hrs